Erectile Dysfunction in Severe Obstructive Sleep Apnea: Effects of CPAP Therapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-05-31

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Obstructive sleep apnea has been linked to erectile dysfunction. Furthermore, small studies suggest that treatment of sleep apnea by continuous positive airway pressure (CPAP) may reverse erectile dysfunction in affected patients. The present study aims to investigate in a larger cohort if severe sleep apnea is independently associated with erectile dysfunction and if 6-12 months of CPAP therapy lead to an improvement of erectile dysfunction.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obstructive Sleep Apnea Erectile Dysfunction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* apnea-hypopnea-index \> 30/h
* no CPAP therapy
* male gender
* 18-80 years of age
* having or attempting to have regular sexual intercourse

Exclusion Criteria

* apnea-hypopnea-index \< 30/h
* already treated by CPAP
* female gender
* age \< 18 or \> 80 years
* not having or not attempting to have regular sexual intercourse

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Richard Schulz

Prof. Dr. Richard Schulz

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Richard Schulz, MD

Role: PRINCIPAL_INVESTIGATOR

University of Giessen Lung Center, Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UGLC

Identifier Type: OTHER

Identifier Source: secondary_id

GERSAN-1

Identifier Type: -

Identifier Source: org_study_id